Archive · 8 Aug 2025
Wockhardt Q1 Net Loss Widens to ₹108 Crore
Wockhardt, a drug company, lost a lot more money in the first part of 2025 than they did the year before.
This is because one of their businesses in the US had to close down.
Even though they lost more money, the amount of money they made stayed about the same as last year.
The company is now working on new medicines and wants to focus on making more money.
They also stopped selling some medicines in the US to help with the losses.
Wockhardt's net loss for Q1 2025 was Rs 108 crore, a significant increase.
The loss was attributed to the liquidation of a US subsidiary under Chapter 7.
Revenue remained nearly flat at Rs 738 crore compared to the previous year.
The company is focusing on profitability and investments in novel antibiotics.
Wockhardt exited its US generics business to reduce losses and focus on innovation.
- Who
- Wockhardt, a pharmaceutical company.
- What
- Wockhardt reported a net loss of Rs 108 crore in Q1 2025.
- When
- In the first quarter (Q1) ended June 30, 2025.
- Where
- The company operates internationally, with specific impacts in the US.
- Why
- Due to impairment from liquidating a US subsidiary and exiting US generics business.
- Net Loss (Q1 2025)
- Rs 108 crore
- Net Loss (Q1 2024)
- Rs 16 crore
- Revenue (Q1 2025)
- Rs 738 crore
- India Business Growth
- 8% (Q1FY26)
- UK Business Growth
- 13% (Q1FY26)
- Irish Business Growth
- 11% (Q1FY26)
- US Subsidiary Liquidation
- Morton Grove Pharmaceuticals Inc.
